Close Menu

NEW YORK – Biolidics said today that its ClearCell FX1 System has obtained a Class I registration from the China National Medical Products Administration.

ClearCell FX1 is a liquid biopsy platform that separates and enriches cancer cells from a blood sample for either quantitation or further analyses like molecular and genomic profiling.

With the NMPA approval, Biolidics can now directly market and sell the platform to hospitals, laboratories, research institutions, and other medical institutions for use in in vitro diagnostic testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.